MIGDAL HA'EMEQ, Israel, Nov. 13, 2013 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-functional lipid ingredients, will ring the NASDAQ Stock Market opening bell in New York, NY today, Wednesday, November 13, 2013. President and Chief Executive Officer, Dr. Ariel Katz, along with other senior executives, will participate in the bell ringing ceremony to commemorate Enzymotec's listing on the NASDAQ Global Select Market on September 27, 2013, under the symbol "ENZY."
"Listing on NASDAQ is a significant accomplishment for Enzymotec and we are proud to participate in the opening bell ceremony," said Dr. Katz. "We are excited about opportunities ahead of our company and we remain focused on profitable growth and building value for our shareholders."
Founded in 1998, Enzymotec has established itself as a global nutritional ingredients and medical foods company. Since the launch of its first product in 2003, the company has developed and launched 13 additional products, generating sales in over 30 countries around the world. Its clinically-validated products include bio-functional lipid-based compounds which are familiar to human body and designed to uniquely address dietary needs and dietary management for prevention of medical disorders and common diseases.
About Enzymotec Ltd.
Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-functional lipid ingredients, as well as final products, based on sophisticated processes and technologies. For more information, visit www.enzymotec.com.
Forward Looking Statement
This release may contain forward-looking statements, which express the current beliefs and expectations of Company management. Such statements involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences the following risks: a high proportion of the sales of our InFat product is sold to end users by a single company in China; we rely on our Swedish joint venture partner to manufacture InFat, and certain matters related to the joint venture are or, based on communications from our joint venture partner, are the subject of disagreement; our gross profits may be adversely affected if we are only able to obtain lower quality krill meal; our ability to obtain krill may be affected by conservation regulation or initiatives; we are dependent on a single facility that houses the majority of our operations; we may not be able to expand our production or processing capabilities or satisfy growing demand; our product development cycle is lengthy and uncertain, and our development or commercialization efforts for our products may be unsuccessful; we are subject to significant and increasing government regulations regarding the sale and marketing of our products; we may not be able to protect our proprietary technology or prevent its unauthorized use by third parties; we are currently subject to litigation, and in the future may become subject to additional litigation, regarding intellectual property rights; and other factors discussed under the heading "Risk Factors" in the Company's final prospectus for its initial public offering filed with the Securities and Exchange Commission on September 30, 2013. Forward-looking statements in this release are made pursuant to the safe harbor provisions contained in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: ICR, LLC Katie Turner 646-277-1228 -or- John Mills 310-954-1105 John.Mills@icrinc.comSource:Enzymotec Ltd.